GreenLight Biosciences (Nasdaq: ENVI), a US-based biotechnology company, and Samsung Biologics (KRX: 207940.KS), a Korea-based global CDMO offering completely integrated end-to-end contract development and manufacturing services, announced on Wednesday that they have entered into a collaboration agreement for the production of GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
The collaboration intends to expedite production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trials and is subject to regulatory approval for commercial sales. It will use GreenLight's present manufacturing process, with technology transfer from GreenLight Biosciences to Samsung Biologics commencing immediately.
GreenLight CEO Andrey Zarur, said, 'We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world. Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients